Navigation Links
Review of probiotic research finds only Bifantis can claim efficacy vs. placebo for IBS symptoms
Date:10/15/2007

PHILADELPHIA October 15, 2007 A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis, Bifidobacterium infantis 35624, the sole ingredient in Align (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Researchers at the University of Michigan conducted the review to evaluate the safety, efficacy and tolerability of probiotics for IBS in randomized controlled trials and found that, with the exception of the Bifidobacterium infantis 35624 studies, most were not designed in a way that made the data possible to validate. The review data were presented this week at the annual American College of Gastroenterology (ACG) conference taking place in Philadelphia, PA.

There is growing interest in medical and patient communities about the use of probiotics in IBS and lots of data has been published about this topic, but its helpful to know the quality of that data before making a treatment decision, said Darren Brenner, MD, lead investigator on this project. Our analysis showed that only this particular strain of probiotic, Bifidobacterium infantis 35624, has valid data for successfully treating IBS symptoms. At this point, we just dont have enough valid data to determine if other probiotics are effective for IBS.

The Study

The goal of this systematic review of randomized controlled trials was to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Criteria for the study included randomized controlled trials testing adults with IBS symptoms using single or combination probiotics versus placebo for IBS symptoms and frequency of adverse events.

Of the 13 trials that met selection criteria, 11 demonstrated sub-optimal study design with inadequate blinding, inadequate trial length, inadequate sample size and lack of proper analysis. Only three studies provided quantifiable data about tolerability and adverse events, and the only probiotic to demonstrate significant improvement in IBS symptoms in appropriately designed studies was Bifidobacterium infantis 35624.

Bifidobacterium infantis 35624 showed significant improvement in the composite score of abdominal pain/discomfort, bloating/distention and bowel movement difficulty compared with placebo. A subsequent study showed that Bifidobacterium infantis 35624 demonstrated superior efficacy to the placebo for the primary outcome measure of abdominal pain/discomfort as well as for secondary measures including bloating/distention, incomplete evacuation, straining and passage of gas.

From our discovery of the bacterium to the description of its genome and biological properties and, finally, to the clinical studies that have made this available to consumers in Align, our primary goal has been to provide accurate information on the benefits of Bifantis, said Eamonn Quigley, MD FACG and professor of Medicine and Human Physiology and Head of the Medical School, National University of Ireland (NUI).


'/>"/>

Contact: Shirley Johnson
Shirley.Johnson@mslpr.com
Manning Selvage & Lee
Source:Eurekalert

Related medicine news :

1. FDA may speed review of new drugs
2. Scientists review SARS
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
5. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
6. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
7. Thumbs up in weight loss for vegetarian diets: scientific review
8. FDA Accords Priority Review For Pediatric Crohns Disease Drug
9. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
10. Review of Pramod Mahajans Injuries
11. Vaticans Council Reviews Condom Usage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... June 01, 2016 , ... Psoriasis: Targets ... risks ”. , As corresponding author Professor Luigi Naldi says “The review in ... and psoriasis. Smoking influences the onset and the severity of psoriasis, and negatively ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... announced it has been included by Gartner, Inc. in the Contact Center Infrastructure ... of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web ...
(Date:5/31/2016)... Walton Beach, Florida (PRWEB) , ... May 31, ... ... technology to Jay Butch of CertainTeed Corporation, he knew it was something that ... is as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The successful implementation ... in their laboratories as well. However, laboratories have different challenges compared to manufacturing environments. ... lean operations in the lab, METTLER TOLEDO has developed the Lean Lab Checklist ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spectrum Aquatics has launched a brand new ADA ... and built with the user in mind. , “Over the last two years our ... an ADA 400 lbs lift is a necessary requirement for certain facilities with specific ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016  A new study highlights the necessity of health literacy ... Journal of the American College of Radiology , a majority of oncology patients undergo ... Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... Israel , May 27, 2016 ... an innovative biopharmaceutical company focused on late-stage drug ... Dexcel Pharma of pivotal batches required ... and Drug Administration (FDA). This follows Kitov,s ... Phase III trial successfully met its primary efficacy ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
Breaking Medicine Technology: